Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Combination of Ranibizumab and Targeted Laser Photocoagulation (CoRaLaII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04444492
Recruitment Status : Recruiting
First Posted : June 23, 2020
Last Update Posted : May 11, 2022
University of Leipzig
Information provided by (Responsible Party):
University of Giessen

Brief Summary:
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of the study). Based on the long-term observation after CoRaLa I study an importantly shorter duration of treatment and a relevant reduction of the total number of re-injections in RL patients is expected.

Condition or disease Intervention/treatment Phase
Central Retinal Vein Occlusion With Macular Edema Drug: Ranibizumab Injection Device: Laser photocoagulation Phase 3

Detailed Description:

Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina and/or the anterior segment is the most serious complication leading to vitreous hemorrhage, retinal detachment and neovascular glaucoma. In serious cases loss of vision is imminent. To date, no causal treatment has been proven to be effective in large trials. Intravitreal injections of drugs that inhibit the vascular endothelial growth factor (VEGF) and other inflammatory factors are the current treatments of choice for ME due to CRVO. Two different anti-VEGF drugs (ranibizumab and aflibercept), and a biodegradable dexamethasone implant are approved by the EMA (European Medicines Agency). Based on data from confirmatory studies anti-VEGF-drugs are recommended as a treatment of first choice in patients with RVO. All intravitreal drugs provide only a temporary effect with need for re-treatment for recurrences of ME. Mean number of ranibizumab application needed in CRVO patients was found to be 7.4 to 10.2 injections in 12 months. A significant number of CRVO patients require treatment over several years. Need for repetitive treatments and ophthalmic controls are a major burden for patients (and their relatives who are required for driving the patients to ophthalmologists) despite of only few adverse events and generally well-tolerated injections. Endophthalmitis is the most severe ocular complication which can be eye-sight-threatening. The more injections are administered, the higher is the cumulative risk of complications. Due to high costs (>1000 € per injection) treatment with repeated injections over years is of significant socio-economic importance, too. Therefore, treatments concepts which would lead to permanent reduction of ME and/or significantly reduce the number of re-injections over long-term periods are the major currently unmet need in patients with RVO.

Until now, several studies evaluated the impact of the additional pan-retinal laser photocoagulation in patients undergoing the anti-VEGF-treatment for the ME due to retinal vein occlusions. However, most of the studies are limited by retrospective design, small number of evaluated patients or lack of the randomization. None of the available prospective randomized studies had sufficient power to finally clarify the benefit of the additional laser treatment. Therefore, there is an unmet need for a large randomized, prospective, multicentric trials.

The proposed study will be the first sufficiently powered trial evaluating the long-term effect of targeted laser photocoagulation performed selectively (targeted) in peripheral areas of non-perfusion in combination with standard anti-VEGF treatment (ranibizumab injections) on the duration of the required intravitreal treatment over time period of 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: blinded BCVA assessor
Primary Purpose: Treatment
Official Title: Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion
Actual Study Start Date : August 25, 2020
Estimated Primary Completion Date : July 30, 2025
Estimated Study Completion Date : July 30, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Ranibizumab+Laser-arm
Ranibizumab injections and additional targeted laser
Drug: Ranibizumab Injection
initial three injections of Ranibizumab - afterwards pro re nata monthly
Other Name: Lucentis

Device: Laser photocoagulation
Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times

Active Comparator: Ranibizumab-arm
Only Ranibizumab injections
Drug: Ranibizumab Injection
initial three injections of Ranibizumab - afterwards pro re nata monthly
Other Name: Lucentis

Primary Outcome Measures :
  1. Efficacy endpoint is the time to treatment success [ Time Frame: up-to 29 months ]
    Time from randomisation until the date of last criteria-based intravitreal injection in case that thereafter a treatment-free period for (at least) 6 months was observed.

Secondary Outcome Measures :
  1. Best corrected visual acuity (BCVA) [ Time Frame: Month 29 ]
    Best corrected visual acuity (BCVA) in number of ETDRS letters (Early Treatment of Diabetes Retinopathy Study) per visit

  2. Central subfield thickness (CST) [ Time Frame: Month 29 ]
    Central subfield thickness (CST) measured by OCT per visit

  3. Number of ranibizumab injections [ Time Frame: Month 29 ]
    Number of ranibizumab injections required until treatment success and up to the end of Observation.

Other Outcome Measures:
  1. Development of neovascularization(s) [ Time Frame: Month 24 ]
    Proportion of subjects developing neovascularization(s) of retina, optic disc, and/or in anterior segment over the total period of observation.

  2. The area of non-perfusion [ Time Frame: Month 24 ]
    The area of non-perfusion (assessed by FA) will be quantified as sum of all areas identified

  3. Vessel density [ Time Frame: Month 24 ]
    Assessed by OCT-angiography, will be quantified by a metric measure with the range [0;1]

  4. Potential visual field loss [ Time Frame: Month 4 and Month 24 ]
    The change between the two timepoints (Months 4 and 24) per arm will be used to characterize the both groups and be compared between treatment arms.

  5. The number of laser treatments and the laser spots given in the experimental group (RL-arm). [ Time Frame: Month 24 ]
    The number of visits with applied laser treatment and the laser spots applied in the experimental group (RL-arm) will be counted for descriptive reasons and be compared between treatment arms.

  6. Health-related quality of life (QoL): Visual Function Questionnaire VFQ25 [ Time Frame: Baseline, Month 12 and Month 24 ]
    Measured by the Visual Function Questionnaire VFQ25

  7. Areal of foveal avascular zone [ Time Frame: Month 24 ]
    Area of the foveal avascular zone (FAZ, assessed by OCT-angiography, will be quantified in [mmm²])

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of macular edema due to central retinal vein occlusion foveal thickness > 250 μm (measured by OCT)
  • Age > 18 years
  • Written informed consent of the patient
  • BCVA score in the study eye between 24 letters (20/320) and 78 letters (20/25) measured in ETDRS chart
  • History of CRVO no longer than 6 months
  • Presence of capillary non-perfusion in peripheral retina larger than 5 disc areas documented in ultra wide-field fluorescein angiography
  • Ability and willingness to attend all scheduled visits and assessments

Exclusion Criteria:

  • CRVO with ischemic maculopathy defined as diameter of the foveolar avascular zone larger than 2 optic disc diameters
  • Macular edema due to another etiology than retinal vein occlusion (e.g. diabetic maculopathy, uveitis, age related macular degeneration, Irvine-Gass syndrome)
  • History of idiopathic central serous chorioretinopathy
  • Presence of vitreoretinal interface disease (e.g. vitreomacular traction, epiretinal membrane), either on clinical examination or in OCT
  • An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates
  • Aphakia in the study eye
  • Scatter laser photocoagulation or macular photocoagulation in the study eye prior to study entry
  • Intraocular or periocular injection of steroids in the study eye prior to study entry
  • Previous use of an anti-VEGF drug in the study eye
  • Cataract surgery or any other intraocular surgery in the study eye within 3 months prior to study entry
  • Uncontrolled glaucoma (defined as intraocular pressure ≥ 30 mm Hg despite treatment with maximal anti-glaucoma medications)
  • History of stroke, myocardial infarction, transient ischemic attacks within 3 months prior to the study
  • Pregnancy (positive urine pregnancy test) or lactation
  • The presence of active malignancy, including lymphoproliferative disorders.
  • History of allergy to fluorescein or any component of the ranibizumab formulation
  • Active intraocular infection
  • Participation in another simultaneous interventional medical investigation or trial
  • Women with child bearing potency without effective contraception (i. e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner) during the conduct of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04444492

Layout table for location contacts
Contact: Matus Rehak, Professor 0049 641 985 438 01
Contact: Yasmine Breitenstein 0049 341 97 16 247

Layout table for location information
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Polyklinik für Augenheilkunde Not yet recruiting
Dresden, Germany, 01307
Contact: Dirk Sandner, Dr.         
Internationale Innovative Ophthalmochirurgie GbR, Klinik für Augenchirurgie Recruiting
Düsseldorf, Germany
Contact: Hakan Kaymak, Dr.         
Universitätsklinikum Klinik für Augenheilkunde Freiburg Recruiting
Freiburg, Germany, 79106
Contact: Hansjürgen Agostini, Prof.         
Universitätsklinikum Gießen, Klinik und Poliklinik für Augenheilkunde Recruiting
Gießen, Germany
Contact: Matus Rehak, Prof. MUDr.         
Hannover MHH Universitätsklinik für Augenheilkunde Recruiting
Hannover, Germany, 30625
Contact: Amelie Pielen, PD. Dr.         
University Hospital of Leipzig Department of Ophthalmology Recruiting
Leipzig, Germany, 04103
Contact: Focke Ziemssen, Prof. Dr.         
Klinikum der Stadt Ludwigshafen Augenklinik Recruiting
Ludwigshafen, Germany, 67063
Contact: Lars-Olof Hattenbach, Prof.         
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg Klinik für Augenheilkunde Recruiting
Marburg, Germany, 35043
Contact: Walter Sekundo, Prof.         
Ludwig-Maximilians-Universität München, Augenklinik Recruiting
München, Germany
Contact: Siegfried Prieglinger, Prof. Dr.         
Augenzentrum am St. Franziskus-Hospital Münster Recruiting
Münster, Germany, 48145
Contact: Georg Spital, Dr.         
Universitätsklinikum Klinik für Augenheilkunde Withdrawn
Münster, Germany, 48149
Universitätsklinikum Tübingen, Department für Augenheilkunde Recruiting
Tübingen, Germany
Contact: Alexandra Schweig, Dr.         
Universitätsklinikum Ulm, Klinik für Augenheilkunde Recruiting
Ulm, Germany
Contact: Armin Hilmar Wolf, Prof. Dr.         
Augen-OP-Zentrum Zschopau, Praxis für Augenheilkunde Recruiting
Zschopau, Germany
Contact: Simo Murovski, Dr.         
Sponsors and Collaborators
University of Giessen
University of Leipzig
Layout table for investigator information
Study Director: Matus Rehak, Professor Department of Ophthalmology Justus-Liebig-Universität Giessen
Layout table for additonal information
Responsible Party: University of Giessen Identifier: NCT04444492    
Other Study ID Numbers: CoRaLaII
First Posted: June 23, 2020    Key Record Dates
Last Update Posted: May 11, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Giessen:
retinal vein occlusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Retinal Vein Occlusion
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents